IVX055 / ImmVirx - LARVOL DELTA

High affinity receptor bio-selected novel oncolytic RNA virus, IVX055, demonstrates potent anti-tumor activity in human NSCLC, hepatocellular carcinoma and bladder cancer with potential for immunotherapeutic combinations (AACR 2026) - "IVX055 exhibits strong preclinical in vitro and in vivo oncolytic activity and tumor selectivity, supporting its continued development. Future studies will explore combination strategies with ICIs, T-cell engagers, ADCs, and bispecific antibodies to enhance efficacy in advanced solid tumours. A phase 1 basket study of intratumoral IVX055 in combination with systemic anti-PD1 therapy in pts (n=32) bearing visceral disease from checkpoint refractory NSCLC, HCC and Cholangiocarcinoma is planned to commence in 2026."

Oncolytic virus • Biliary Cancer • Bladder Cancer • Cholangiocarcinoma • Genito-urinary Cancer • Hepatocellular Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Novel oncolytic RNA viruses, IVX037 and IVX055, demonstrate potent antitumor activity (AACR 2025) - P1 | "The promising preclinical anti-tumor activity of IVX037 and IVX055 against a wide range of human malignancies warrants further clinical evaluation in combination with novel immunotherapy strategies. To this end, IVX037 is currently being investigated in an ongoing Phase 1b combination trial with sintilimab (anti-PD-1) in patients with advanced MSS-CRC, gastroesophageal, and ovarian cancer (NCT05427487). Future plans for IVX055 include evaluation in combination with immune checkpoint therapy in patients with advanced non-small cell lung cancer (NSCLC) bearing metastatic liver disease."

IO biomarker • Oncolytic virus • Bladder Cancer • Colorectal Cancer • Gastric Cancer • Genito-urinary Cancer • Hepatocellular Cancer • Liver Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor • MSLN • PD-L1

ImmVirX receives $3.77M R&D tax refund for FY23 (ImmVirX Press Release) - "ImmVirX Pty Limited...has received a $3,771,296 Research and Development (R&D) tax refund as part of the Australian Federal Government’s R&D Tax Incentive programme. This amount is based on the R&D undertaken by ImmVirX in the financial year ended 30 June 2023...The refund received by ImmVirX will contribute to the development of its investigational products IVX037 and IVX055 as well as other discovery programmes. IVX037 is progressing in the clinic with a Phase 1 study which is active across multiple clinical sites in Australia and will progress into an evaluation of IVX037 in combination with an immune checkpoint inhibitor therapy mid-CY24....'this funding will support the continued expansion of our research team in Newcastle and allow us to broaden and accelerate our clinical programme with the goal to eventually develop new therapies for patients with colorectal, gastric, ovarian and liver cancer.'"

Financing • Trial status • Colorectal Cancer • Gastric Cancer • Gastrointestinal Cancer • Gynecologic Cancers • Oncology • Ovarian Cancer • Solid Tumor